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cancer treatment ranges from €10,251 to €13,934). The national
ICER was €26,361 per QALY, but the net cost per subject vac-
cinated differed across regions impacting the affordability to
vaccinate multiple cohorts 12-years/catch-up to 16-years. CON-
CLUSIONS: National analyses, using national ‘average’ data, are
the necessary starting point for the evaluation of new health
technologies, addressing centralized regulatory agency require-
ments. However, in the Italian scenario, characterized by decen-
tralization and local autonomy, a further level of detail is
essential in order to describe the regional impact to budget
holders thereby better informing local decision makers and facili-
tating the uptake of cost-effective health care interventions.
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OBJECTIVES: Capecitabine’s mCRC licence was recently
extended supporting its use in combination therapy. This study
evaluated the cost effectiveness of replacing FOLFOX, with
XELOX. METHODS: Based on results from phase 3 trials,
demonstrating that XELOX is non-inferior to FOLFOX4
(NO16966 1st line; NO16967 2nd line), a cost minimisation
analysis was performed evaluating incremental costs from the
start of treatment until disease progression. Dose, treatment dura-
tion, adverse event frequency and the probability of central venous
access device (CVAD) replacement were taken directly from the
NO16966/7 trials. Drug costs were based on the UK list price.
Administration, pharmacy and adverse event costs were taken
from NHS reference costs 2005/6, the literature, and previous
technology appraisals. Clinical practice assumptions were: 10%
and 100% of XELOX and FOLFOX patients receive a CVAD
respectively; 25% of 5FU infusions require an overnight stay in
hospital, the remaining 75% use an ambulatory pump at home;
30% of patients receive hospital funded transport. Uncertainty
was explored via one-way sensitivity analysis and a scenario of
FOLFOX6 being replaced in 1st line (ceteris paribus) was also
evaluated. RESULTS: Per patient, replacing FOLFOX4 with
XELOX, saved (1st/2nd line) £578/£498 drug acquisition, £773/
£341 CVAD placement, £8078/£5561 pharmacy and administra-
tion, and £173/£17 adverse event costs. Total savings were £9611
and £6405 1st and 2nd line respectively. In all of the scenarios
evaluated in the sensitivity analysis XELOX was cost saving by
more than £8636 per patient 1st line, and £5702 2nd line, com-
pared to FOLFOX4. XELOX remained cost saving (~£6500)
when compared to FOLFOX6. CONCLUSIONS: Replacing
FOLFOX with XELOX offers the NHS considerable savings in
terms of administration and pharmacy, and to a lesser extent drug
acquisition costs, with equivalent efﬁcacy. Additionally patients
may prefer XELOX due to the reduction in hospital administra-
tion visits and probability of requiring a CVAD.
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OBJECTIVES: To evaluate the effect of a nurse telephone
follow-up as a strategy for improving therapeutic adherence
among outpatients with schizophrenia. METHODS: A 16–week,
open, multicentre, randomised controlled trial. Patients fulﬁlled
criteria for schizophrenia (DSM-IV TR criteria). To be eligible,
patients had to be ambulatory in treatment with an oral antip-
sychotic agent. Participants were randomised to receive monthly
telephone calls from a nurse of mental health center or standard
clinical follow-up. Phone calls were performed at weeks 4, 8, and
12 in the intervention arm. The calls consisted of a brief inter-
view to assess treatment compliance and Drug Attitude Inventory
(DAI-10). A compliance with60% of doses was used to classify
patients as compliant. Primary endpoint was the difference in the
percentage of compliant patients after nurse telephone follow-up
versus control group at week 16. Secondary endpoints included
socio-demographic data, past mental health diagnosis, Clinical
Global Impression-Schizophrenia (CGI-SCH), DAI-10, and
Euroqol EQ-5D. Study protocol was approved by a local Ethical
Committee and all patients provided written informed consent.
RESULTS: A total of 865 patients were studied, 65% men. Mean
age: 40.08 years (SD = 11.6). Baseline socio-demographic and
main clinical characteristics were similar between both groups:
mean time from diagnosis: 13.08 years (SD = 9.5), mean number
of hospitalisations in the last 5 years: 2.23 (SD = 2.7), mean time
from last relapse: 3.1 years (SD = 3.9). A total of 88.2% (374)
patients in the intervention arm were compliant vs 90.0% (397)
in control arm. At baseline, mean CGI-SCH, DAI-10, and
EQ-5D scores were similar in both groups. At week 16, 410
(96.7%) patients fulﬁlled compliance criteria in the intervention
group vs 402 (91.1%) in the control group. An absolute differ-
ence of 5.5% was found between groups (CI95%, 2.3–8.6%;
p = 0.0007); OR 3.57 (CI95%, 1.81–7.04). Mean global CGI-
SCH and DAI-10 scores were better in the intervention arm: 3.07
vs 3.25 p = 0.009; 6.05 vs 5.19 p < 0.0001, respectively. CON-
CLUSIONS: Despite a high baseline rate of compliance of the
studied population, nurse telephone intervention increased
antipsychotic adherence. A nurse telephone follow-up could be a
complementary strategy to improve therapeutic adherence in
schizophrenic patients.
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OBJECTIVES: To assess adherence, persistence, costs and
Health-Related-Quality-of-Life (HRQoL) in patients undergoing
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